Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from National Institutes of Health

Q&A: Penn ethicist Zeke Emanuel has another life as a venture capitalist

Ezekiel Emanuel chairs the department of medical ethics and health policy at the University of Pennsylvania. He started the bioethics department at the National Institutes of Health, helped shape U.S. health-care policy as a senior aide in the Obama administration, served on President Joe Biden's COVID-19 task force, and advocates…

The Philadelphia Inquirer

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Discovering new ways to use existing drugs can come about intentionally or by chance.

The Conversation

New data-sharing requirements from the National Institutes of Health are a big step toward more open science – and potentially higher-quality research

Starting on Jan. 25, 2023, many of the 2,500 institutions and 300,000 researchers that the U.S. National Institutes of Health supports will need to provide a formal, detailed plan for publicly sharing the data generated by their research. For many in the scientific community, this new NIH Data Management and…

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

COVID’s ‘silver lining’: Research breakthroughs for chronic disease, cancer and the common flu

The billions of dollars invested in COVID vaccines and COVID-19 research so far are expected to yield medical and scientific dividends for decades, helping doctors battle influenza, cancer, cystic fibrosis and far more diseases.

Tribune News Service

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

Benzinga

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Los Angeles Times

Read news from The Economist, FT, and more,
with one subscription

Mayo Clinic Minute: How COVID-19 has affected cancer care

Cancer has not rested during the COVID-19 pandemic, as is evident by the number of people diagnosed with cancer since 2020. Research published by the National Institutes of Health suggests that delayed screening during the pandemic has led to thousands of deaths and make cancers more difficult to treat when…

Tribune News Service

BHU scientists bring a ray of hope in Diabetic foot ulcer treatment

Scientists from the Banaras Hindu University (BHU) have found a cure for chronic wounds, particularly diabetic foot ulcers. The research findings have been published in the National Centre for Biotechnology Information (NCBI), National Institutes of Health (NIH), US.

The Times of India

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Pennsylvania

121 stories

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Banaras Hindu University

17 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.